Aripiprazole is a small-molecule drug that the ChEMBL database records as molecule CHEMBL1112. ChEMBL gives 2002 as the year of its first approval and a maximum clinical phase of 4, which means it has reached approved use, and the record shows it has not been withdrawn. The same record flags the drug as available by mouth and by parenteral routes, and not as a topical product. ChEMBL lists its approved indications as schizophrenia, bipolar disorder, depressive disorder, autistic disorder, Tourette syndrome, psychotic disorders, psychomotor agitation and aggression, so it belongs among the medicines used in psychiatric and neurological care. Under the WHO Anatomical Therapeutic Chemical system it sits in the nervous system group. This entry records classification and approval facts only and is not medical advice.
Facts
Classification
Approval Status Route of Administration Route of Administration First Approved / Isolated Year Connections
Treats
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
Sources
1. Aripiprazole (ChEMBL)
ChEMBL molecule CHEMBL1112, first_approval
"first_approval": 2002
ChEMBL molecule CHEMBL1112, max_phase
"max_phase": "4.0"
ChEMBL molecule CHEMBL1112, oral flag
"oral": true
View the Source2. RxNav RxClass, National Library of Medicine: RxClass ATC classes of Aripiprazole
RxNav RxClass, National Library of MedicineRxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code N05AX (main group N)Quote, RxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code N05AX (main group N)
"classId": "N05AX", "className": "Other antipsychotics", "classType": "ATC1-4"
View the Source 3. Aripiprazole (Wikipedia)
Lead, route of administrationQuote, Lead, route of administration
Aripiprazole is taken by mouth or via injection into a muscle.
View the Source ChEMBL, EMBL-EBI: Aripiprazole approved indications (ChEMBL)
ChEMBL, EMBL-EBIChEMBL drug_indication record, maximum phase 4, MeSH heading Psychotic Disorders
"max_phase_for_ind": "4.0", "mesh_heading": "Psychotic Disorders", "molecule_chembl_id": "CHEMBL1112"
ChEMBL drug_indication record, maximum phase 4, MeSH heading Aggression
"max_phase_for_ind": "4.0", "mesh_heading": "Aggression", "molecule_chembl_id": "CHEMBL1112"
Treats: Tourette Syndrome, drug_indication record, maximum phase 4, MeSH heading Tourette Syndrome
"max_phase_for_ind": "4.0", "mesh_heading": "Tourette Syndrome", "molecule_chembl_id": "CHEMBL1112"
Treats: Psychomotor agitation, drug_indication record, maximum phase 4, MeSH heading Psychomotor Agitation
"max_phase_for_ind": "4.0", "mesh_heading": "Psychomotor Agitation", "molecule_chembl_id": "CHEMBL1112"
Treats: Bipolar Disorder, drug_indication record, maximum phase 4, MeSH heading Bipolar Disorder
"max_phase_for_ind": "4.0", "mesh_heading": "Bipolar Disorder", "molecule_chembl_id": "CHEMBL1112"
Treats: Schizophrenia, drug_indication record, maximum phase 4, MeSH heading Schizophrenia
"max_phase_for_ind": "4.0", "mesh_heading": "Schizophrenia", "molecule_chembl_id": "CHEMBL1112"
Treats: Autism, drug_indication record, maximum phase 4, MeSH heading Autistic Disorder
"max_phase_for_ind": "4.0", "mesh_heading": "Autistic Disorder", "molecule_chembl_id": "CHEMBL1112"
Treats: Depression, drug_indication record, maximum phase 4, MeSH heading Depressive Disorder
"max_phase_for_ind": "4.0", "mesh_heading": "Depressive Disorder", "molecule_chembl_id": "CHEMBL1112"
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.